Hypercholesterolemia

The past 18 months have noticeably shifted the LDL-lowering landscape: An ESC/EAS-Focused Update 2025 sharpens the indication thresholds, real-world data confirm the benefit of early combinations after myocardial infarction, bempedoic acid confirms robust outcome effects in statin intolerance, siRNA therapy gains reach – and positive phase 3 topline results on an oral PCSK9 inhibitor are available for the first time. This review distills the latest evidence and translates it into consistent strategies for cardiac care – focusing on secondary prevention, statin intolerance, FH subgroups and the safety of very low LDL-C levels.